[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Damaj G, Braud AC, Hermine O: [Anemia and chemotherapy of malignant hemopathies]. Bull Cancer; 2003 Apr;90 Spec No:S144-51
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anemia and chemotherapy of malignant hemopathies].
  • [Transliterated title] Anémie et chimiothérapie des hémopathies malignes.
  • Anemia is a frequent symptom encountered in hematological malignancies at diagnosis or in the course of the disease.
  • Allogeneic transfusions were, until recently, the only treatment available and used only for severe anemia.
  • Erythropoietin is currently an important alternative especially for treatment and even to prevent severe anemia.
  • It has been assessed for the treatment of chemotherapy related anemia in NHL, myeloma and CLL with a significant reduction of blood transfusions and prevention of grade 3-4 anemia in 51% of patients.
  • In the setting of allogeneic bone marrow transplantation, it reduces the time to red cell engraftment and probably the number of blood cell unit per patient in contrast with autologous stem cell transplant.
  • [MeSH-major] Anemia. Erythropoietin / therapeutic use. Hematologic Neoplasms / drug therapy
  • [MeSH-minor] Hematologic Diseases / complications. Hematopoietic Cell Growth Factors / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Myelodysplastic Syndromes / complications. Recombinant Proteins

  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856426.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hematopoietic Cell Growth Factors; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  • [Number-of-references] 39
  •  go-up   go-down


2. Boccadoro M, Omedé P, Dominietto A, Palumbo A, Bringhen S, Giaretta F, Ortolano B, Triolo S, Pileri A: Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant; 2000 Jan;25(1):25-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.
  • Multiple myeloma (MM) is characterized by the expansion of tumor plasma cells in bone marrow (BM), but neoplastic cells have been consistently detected in peripheral blood (PB).
  • Peripheral blood progenitor cell (PBPC) collections have been widely used to support high-dose therapy for MM patients.
  • Malignant plasma cell reinfusion could negatively affect response rate and survival, as demonstrated in other hematological malignancies.
  • To address this issue, the relationship between the number of reinfused plasma cells, response to chemotherapy and event-free survival (EFS) have been analyzed.
  • Sixty-four MM patients were treated with intensified chemotherapy at diagnosis.
  • There was no correlation between the number of reinfused plasma cells and response rate after this intensified chemotherapy: patients attaining complete remission received 3.6 x 106/kg CD38+ cells, while those with a partial or no response received 5.6 and 2.9 x 106/kg CD38+ cells.
  • Bone Marrow Transplantation (2000) 25, 25-29.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Multiple Myeloma / physiopathology. Multiple Myeloma / therapy. Plasma Cells / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10654010.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  •  go-up   go-down


3. Willmott F, Agarwal N, Heath M, Stevens J, Chakravarti S: Plasma cell myeloma diagnosed in pregnancy. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell myeloma diagnosed in pregnancy.
  • Plasma cell myeloma (PCM) is an essentially incurable neoplastic disorder of terminally differentiated B cells.
  • The clinical picture is one of bone marrow failure, due to infiltration of the marrow by malignant plasma cells; renal failure due to damage to renal tubules by the excess light chains and pain due to lytic lesions of the bones.
  • [MeSH-major] Multiple Myeloma / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow / pathology. Cesarean Section. Disease Progression. Female. Fetal Growth Retardation / diagnosis. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Male. Neoplasm Staging. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / drug therapy. Puerperal Disorders / pathology. Remission Induction

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004 Jun;86-A(6):1284-8 [15173303.001]
  • [Cites] Blood. 1966 Jul;28(1):102-11 [5944257.001]
  • [Cites] Obstet Gynecol. 1968 Jun;31(6):811-20 [5742077.001]
  • [Cites] West Indian Med J. 1971 Jun;20(2):97-100 [5110487.001]
  • [Cites] Cancer. 1974 Oct;34(4):1018-22 [4417641.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):38-42 [3800603.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):513-5 [2304725.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):516-8 [2304726.001]
  • [Cites] Int J Gynaecol Obstet. 1991 Aug;35(4):341-2 [1682183.001]
  • [Cites] Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):217-9 [7847542.001]
  • [Cites] Leuk Res. 1997 Sep;21(9):885-8 [9393604.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):108-12 [15923168.001]
  • [Cites] J Obstet Gynaecol. 2006 Oct;26(7):693-5 [17071446.001]
  • [Cites] Nephrol Dial Transplant. 2007 Dec;22(12):3652-5 [17875572.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Jan;100(1):89-90 [17825829.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):181-2 [18682949.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):214-5 [14597255.001]
  • (PMID = 22791481.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027817
  •  go-up   go-down


Advertisement
4. Bladé J, Cibeira MT, Fernández de Larrea C, Rosiñol L: Multiple myeloma. Ann Oncol; 2010 Oct;21 Suppl 7:vii313-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma.
  • Multiple myeloma (MM) constitutes 1% of malignant diseases and 15% of haematological malignancies.
  • The diagnosis of MM requires the presence of an M-protein in serum and/or urine, increased bone marrow plasma cells and related organ or tissue impairment.
  • Cytogenetic status, serum β2-microglobulin and response to therapy are the key prognostic factors.
  • The treatment of younger patients with MM should include a triple-agent induction regimen (i.e. bortezomib/thalidomide/dexamethasone), autologous stem cell transplantation (ASCT) and consolidation and maintenance incorporating novel agents along with sequential minimal residual disease studies to determine for how long treatment is still of benefit.
  • In relapsing patients, the choice of salvage therapy should depend on: (i) the components of initial therapy, (ii) the degree and duration of response, (iii) type of relapse: aggressive versus indolent, (iv) previous toxicities and (v) age and performance status.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943635.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Kamble R, Wilson CS, Fassas A, Desikan R, Siegel DS, Tricot G, Anderson P, Sawyer J, Anaissie E, Barlogie B: Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma; 2005 Aug;46(8):1137-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural effusion of multiple myeloma: prognostic factors and outcome.
  • Malignant pleural effusion (MPE) in multiple myeloma (MM) is rare.
  • To delineate optimal treatment and prognostic variables in these patients, we reviewed 11 MM patients with MPE.
  • MPE developed at median of 12 months from diagnosis of MM.
  • The initial diagnosis of MPE was based on positive cytology (n=9), pleural fluid cIg/DNA (n=9) or pleural fluid cytogenetics (n=4).
  • Pleural tissue infiltration was found on pleural biopsy and autopsy in one patient each.
  • Systemic chemotherapy comprising dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) (n=7) and pleurodesis (n=7) were effective in resolving MPE but survival was short.
  • High dose chemotherapy with peripheral blood stem cell support for MPE in six patients conferred no clear survival advantage.
  • Patients with bone marrow complex karyotypic abnormalities including deletion-13 (n=9) had a shorter (median--18 months) overall survival compared to patients with normal cytogenetics (median--38 months).
  • MPE in patients with MM is often associated with high-risk disease including deletion 13 chromosomal abnormality and heralds a poor prognosis despite aggressive local and systemic treatment.
  • [MeSH-major] C-Reactive Protein / metabolism. L-Lactate Dehydrogenase / metabolism. Multiple Myeloma / complications. Multiple Myeloma / diagnosis. Pleural Effusion, Malignant / complications. Pleural Effusion, Malignant / diagnosis. beta 2-Microglobulin / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Karyotyping. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085553.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / beta 2-Microglobulin; 9007-41-4 / C-Reactive Protein; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


6. Svaldi M, Tappa C, Gebert U, Bettini D, Fabris P, Franzelin F, Osele L, Mitterer M: Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Ann Hematol; 2001 Jul;80(7):393-7
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation.
  • Technetium-99m-sestamibi (MIBI) is a radionuclide tracer taken up by different malignant tumors.
  • Of these 58 MIBI scans were carried out in 46 myeloma patients: 15 at diagnosis, 14 during conventional chemotherapy, and 29 following high-dose sequential therapy and autologous peripheral blood progenitor support.
  • A positive MIBI scan was exhibited by lof 10 with non-myeloma cancers and 2 of 20 with MGUS.
  • In contrast, all stage II and III multiple myelomas (MM) were positive at diagnosis.
  • Therefore, the sensitivity of the MIBI scan at diagnosis was 100%, whereas the specificity in this cohort was 93%.
  • In comparison to conventional skeletal radiographs, MIBI scans recognized a higher number of myeloma lesions at diagnosis.
  • MIBI scans remained positive in all patients during conventional chemotherapy, and there was a direct correlation between MIBI result and clinical outcome of patients following high-dose therapy.
  • A diffuse MIBI pattern reflected a higher bone marrow plasma cell number.
  • In five patients, histologically or cytologically verified soft tissue myeloma lesions were correctly diagnosed by MIBI scan, while all plain radiographs showed none of them.
  • MIBI has proven to be an effective tool in diagnosing biologically active myeloma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Multiple Myeloma / radionuclide imaging. Multiple Myeloma / therapy. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Period. Sensitivity and Specificity. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11529464.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


7. Pilarski LM, Giannakopoulos NV, Szczepek AJ, Masellis AM, Mant MJ, Belch AR: In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clin Cancer Res; 2000 Feb;6(2):585-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease.
  • DNA aneuploidy characterizes a proportion of malignant bone marrow (BM)-localized plasma cells in multiple myeloma (MM).
  • Although all normal B cells and some malignant B cells are diploid, hyperdiploidy is likely to be exclusive to those that are malignant.
  • Hyperdiploid MM B cells express CD34 and have clonotypic IgH transcripts, confirming them as part of the malignant clone.
  • DNA hyperdiploid PBMCs were most frequent among untreated patients and were significantly reduced after chemotherapy.
  • Diploid B cells were significantly more frequent after chemotherapy than at diagnosis.
  • The DNA hyperdiploidy of CD34+ clonotypic B cells suggests these cells may be clinically important constituents of the myeloma clone and that they may play a direct role in the spread of myeloma.
  • [MeSH-major] B-Lymphocytes / immunology. Gene Rearrangement. Genes, Immunoglobulin. Immunoglobulin Heavy Chains / genetics. Multiple Myeloma / genetics. Multiple Myeloma / immunology
  • [MeSH-minor] Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Diploidy. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Prognosis. T-Lymphocytes / immunology. Transcription, Genetic

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10690543.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


8. Karam AR, Semaan RJ, Buch K, Shankar S: Extramedullary duodenal plasmacytoma presenting with gastric outlet obstruction and painless jaundice. J Radiol Case Rep; 2010;4(8):22-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant plasma cells in multiple myeloma are predominantly confined to the medullary space of the skeletal system, therefore the disease course will be dominated by signs and symptoms related to bone marrow infiltration and destructive bone lesions with their consequences as well as abnormal protein production.
  • We report a case of duodenal extramedullary plasmacytoma presenting with gastric outlet obstruction and painless jaundice, in a patient treated for multiple myeloma.
  • Diagnosis was first suggested on imaging, and proved by endoscopic biopsy.
  • The duodenal mass resolved following chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470749.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303390
  • [Keywords] NOTNLM ; Multiple myeloma / duodenal plasmacytoma / extramedullary multiple myeloma / gastric outlet obstruction / gastrointestinal involvement / painless jaundice
  •  go-up   go-down


9. Burkhardt O, Dickgreber NJ, Bühling F, Waldburg N, Merker HJ, Welte T: [Diagnosis of multiple myeloma by demonstrating plasma cells in bronchoalveolar lavage]. Dtsch Med Wochenschr; 2003 Sep 19;128(38):1951-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of multiple myeloma by demonstrating plasma cells in bronchoalveolar lavage].
  • HISTORY AND CLINICAL FINDINGS: A 61-year-old man was transferred from a peripheral hospital with the diagnosis of interstitial lung disease and an unclear mediastinal tumour.
  • At the time of admission the patient had congestive heart disease NYHA class IV.
  • Aspiration and investigation of the bone marrow verified the diagnosis of a IgG multiple myeloma, highly differentiated characterised by monoclonal expression of light-lambda chains.
  • DIAGNOSIS: Multiple myeloma, IgG-lambda, stage IIA.
  • THERAPY AND CLINICAL COURSE: Chemotherapy with prednisolone and melphalan was initiated.
  • His general condition increased after administration of the first cycle of chemotherapy.
  • CONCLUSION: Cardiopulmonary involvement is seldom seen in multiple myeloma but should be excluded when clinical symptoms are present.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoalveolar Lavage Fluid / cytology. Multiple Myeloma / diagnosis. Plasma Cells. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Ascites. Bence Jones Protein / metabolism. Bence Jones Protein / urine. Bone Marrow / pathology. Humans. Male. Melphalan / therapeutic use. Microscopy, Electron. Middle Aged. Prednisolone / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14502447.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9006-99-9 / Bence Jones Protein; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  •  go-up   go-down


10. Oriol A, Valverde D, Capellades J, Cabañas ME, Ribera JM, Arús C: In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow. MAGMA; 2007 Apr;20(2):93-101
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow.
  • OBJECT: Magnetic resonance imaging (MRI) is the gold standard non-invasive technique to detect malignant disease in the bone marrow.
  • We performed proton MRS to patients with multiple myeloma (MM) at diagnosis and after treatment to investigate the possible correlation of MRS data with response to therapy.
  • Post treatment MRS was available in 16 patients of whom 11 (69%) presented an LWR increase, this included all complete responders (8/8, 100%, P = 0.012).
  • A post-treatment LWR value equal to or larger than one is proposed as a non-invasive marker of complete response to treatment.
  • CONCLUSION: Only patients responding to treatment presented a significant increase in bone marrow LWR after therapy.
  • MRS may provide an adequate quantification of response to chemotherapy in patients with MM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Bone Marrow / metabolism. Lipids / analysis. Magnetic Resonance Spectroscopy / methods. Multiple Myeloma / diagnosis. Multiple Myeloma / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Lumbar Vertebrae / metabolism. Male. Middle Aged. Prognosis. Protons. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] J Magn Reson. 2004 Sep;170(1):164-75 [15324770.001]
  • [Cites] Magn Reson Med. 1991 Nov;22(1):111-27 [1798386.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2127-47 [9310464.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Radiology. 1996 Oct;201(1):243-6 [8816551.001]
  • [Cites] J Magn Reson. 1997 Nov;129(1):35-43 [9405214.001]
  • [Cites] J Comput Assist Tomogr. 1992 May-Jun;16(3):454-60 [1592931.001]
  • [Cites] AJR Am J Roentgenol. 1993 Mar;160(3):572-4 [8430555.001]
  • [Cites] Ann Hematol. 1993 Jan;66(1):3-13 [8381677.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1696-704 [15569733.001]
  • [Cites] AJR Am J Roentgenol. 1993 May;160(5):1053-7 [8470575.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):465-71 [7529528.001]
  • [Cites] Radiology. 1992 Apr;183(1):39-46 [1549692.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2697-702 [11023500.001]
  • [Cites] Magn Reson Imaging. 1990;8(6):779-89 [2266805.001]
  • [Cites] MAGMA. 2001 May;12(2-3):141-52 [11390270.001]
  • [Cites] Radiology. 1996 May;199(2):541-9 [8668809.001]
  • [Cites] Radiology. 2000 Jun;215(3):910-6 [10831721.001]
  • [Cites] Radiology. 2003 Dec;229(3):710-7 [14593191.001]
  • [Cites] J Magn Reson Imaging. 1996 Jul-Aug;6(4):667-74 [8835961.001]
  • [Cites] Radiology. 2004 Apr;231(1):11-23 [14990813.001]
  • [Cites] Radiologe. 2000 Aug;40(8):700-9 [11006940.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):649-55 [9401079.001]
  • [Cites] Cranio. 2004 Apr;22(2):115-23 [15134411.001]
  • [Cites] J Magn Reson Imaging. 2001 Feb;13(2):263-8 [11169833.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1545-51 [8694524.001]
  • [Cites] Invest Radiol. 1995 Apr;30(4):254-65 [7635676.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):251-6 [7799027.001]
  • [Cites] Hematol J. 2001;2(4):272-8 [11920260.001]
  • [Cites] Magn Reson Med. 1992 Aug;26(2):207-17 [1513248.001]
  • [Cites] AJR Am J Roentgenol. 1996 Aug;167(2):355-8 [8686603.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Radiology. 1994 Nov;193(2):441-6 [7972760.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):541-8 [16161078.001]
  • [Cites] Radiology. 1992 Dec;185(3):833-40 [1438772.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1134-43 [14648561.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • (PMID = 17410391.001).
  • [ISSN] 0968-5243
  • [Journal-full-title] Magma (New York, N.Y.)
  • [ISO-abbreviation] MAGMA
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipids; 0 / Protons
  •  go-up   go-down


11. Dieleman FJ, Dekker AW: [Kahler's disease. Multiple myeloma]. Ned Tijdschr Tandheelkd; 2007 May;114(5):228-30
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kahler's disease. Multiple myeloma].
  • Kahler's disease, multiple myeloma, is a malignant condition of unbridled multiplication of plasma cells in bone marrow.
  • Clinical features are anaemia, pain in the affected bones, spontaneous bone fractures and increased infection susceptibility.
  • With the present chemotherapy a good response is seen in 50-70% of patients, but complete response occurs only in a minority of patients.
  • Radiotherapy is often used in addition to chemotherapy.
  • In order to minimize the risk of complications, it is advocated to be in touch with the patients haematologist before starting an invasive oral treatment.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Multiple Myeloma / diagnosis
  • [MeSH-minor] Bone Resorption. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17552301.001).
  • [ISSN] 0028-2200
  • [Journal-full-title] Nederlands tijdschrift voor tandheelkunde
  • [ISO-abbreviation] Ned Tijdschr Tandheelkd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Claudio JO, Stewart AK: Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma. Am J Pharmacogenomics; 2005;5(1):35-43
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.
  • Pharmacogenomic studies in multiple myeloma, a neoplasia of clonally expanded malignant bone marrow plasma cells, are helping to set the stage for individualized therapy.
  • Although relatively few in numbers, these studies are already providing new therapeutic targets and avenues for drug discoveries as well as contributing to novel prognostic markers in multiple myeloma.
  • High-throughput mutation screening of the kinome promises to identify further novel targets for therapy.
  • Genetics and gene expression profiling technology have improved molecular-based patient stratification and prognostic staging, expanded knowledge of the molecular mechanism of chemotherapeutic agents, and provided a better understanding of myeloma bone disease.
  • The use of pharmacogenomic strategies in myeloma is thus already changing medical practice.
  • [MeSH-major] Multiple Myeloma / diagnosis. Multiple Myeloma / genetics. Pharmacogenetics / methods. Pharmacogenetics / trends

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727487.001).
  • [ISSN] 1175-2203
  • [Journal-full-title] American journal of pharmacogenomics : genomics-related research in drug development and clinical practice
  • [ISO-abbreviation] Am J Pharmacogenomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 87
  •  go-up   go-down


13. Kumar L, Verma R, Radhakrishnan VR: Recent advances in the management of multiple myeloma. Natl Med J India; 2010 Jul-Aug;23(4):210-8
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the management of multiple myeloma.
  • Multiple myeloma is a disease of malignant plasma cells in the bone marrow.
  • Interaction of malignant plasma cells with the bone marrow microenvironment plays a key role in the pathogenesis of the disease.
  • The Introduction of two new classes of molecules, namely immunomodulators (e.g. thalidomide, lenalidomide), and proteasome inhibitors (e.g., bortezomib) has led to improvement in the management of myeloma.
  • Induction therapy with these novel drugs in combination with dexamethasone is associated with higher response rates including complete response in one-fourth of patients with bortezomib combinations.
  • Further consolidation with intensive chemotherapy supported by autologous stem cell transplant in young, eligible patients results in complete response in 50%-70% of patients with improved survival.
  • Simplified criteria for staging, uniform response criteria, more sensitive methods for detection of residual disease (immunofixation and free light chain assay), and recognition of potential adverse cytogenetic and genomic abnormalities have further refined the management of patients with myeloma.
  • Along with earlier diagnosis, improved treatment and better management of complications have resulted in longer disease control and survival with a better quality of life.
  • [MeSH-major] Multiple Myeloma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Cytogenetics. Early Diagnosis. Humans. Neoplasm, Residual / diagnosis. Prognosis. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21192514.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] India
  •  go-up   go-down


14. Park S, Kim C, Kim H, Hong D, Lee S, Won J, Park H, Bae S, Lee Y, Kim E, Jung Y: The usefulness of interphase fluorescence in situ hybridization at diagnosis of myeloma in addition to metaphase cytogenetics. J Clin Oncol; 2009 May 20;27(15_suppl):e19558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of interphase fluorescence in situ hybridization at diagnosis of myeloma in addition to metaphase cytogenetics.
  • : e19558 Background: Multiple myeloma is characterized by the accumulation of malignant plasma cells within the bone marrow and regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants.
  • The clinical heterogeneity of myeloma is dictated by the cytogenetic aberrations present in the clonal plasma cells.
  • Fluorescence in situ hybridization (FISH) overcomes the limitations of standard cytogenetics and allows for the detection of numerical and structural chromosomal abnormalities in both metaphase spreads and interphase nuclei.
  • And it should be used in the routine evaluation of multiple myeloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961070.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bayer-Garner IB, Smoller BR: The spectrum of cutaneous disease in multiple myeloma. J Am Acad Dermatol; 2003 Apr;48(4):497-507
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of cutaneous disease in multiple myeloma.
  • BACKGROUND: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by a clonal proliferation of plasma cells that produces a monoclonal protein.
  • DESIGN: We reviewed 2357 pathology reports of all patients with a diagnosis of MM to find those who had undergone a skin biopsy.
  • Files were searched for bone-marrow diagnosis, and for type and number of transplants.
  • Skin biopsy specimen diagnoses included neoplastic lesions, (111; 73 malignant, 38 benign), graft-versus-host disease (120), drug-related lesions (46), cutaneous eruption of lymphocyte recovery (3), thrombocytopenia-related lesions (9), normolipemic plane xanthoma (1), amyloidosis (1), Sweet's syndrome (7), panniculitis (1), papulosquamous lesions (18), bullous diseases (17), vasculitis (11), infectious lesions (41), granulomatous dermatitis (6), alopecia cicatrisata (1), nonspecific lesions (77), and unrelated lesions (2).
  • CONCLUSIONS: Skin biopsy specimens from patients with MM less than 60 days from transplant most commonly show sequelae of the transplant such as graft-versus-host disease, Grover's disease (as a result of leukocytopenia and fever, waiting for engraftment), drug eruptions, chemotherapy effect, thrombocytopenic effect, cutaneous eruption of lymphocyte recovery, and Sweet's syndrome (possibly as a result of granulocyte-macrophage colony-stimulating factor).
  • Biopsy specimens taken more than 60 days from transplant most commonly show graft-versus-host disease, drug eruptions, and Sweet's syndrome but also show unrelated conditions such as neoplastic lesions, nevi, papulosquamous lesions, vasculitis, infections, and nonspecific changes.
  • [MeSH-major] Multiple Myeloma / complications. Paraneoplastic Syndromes / pathology. Skin Diseases / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Bone Marrow Transplantation / adverse effects. Female. Graft vs Host Disease / pathology. Humans. Male. Middle Aged. Skin / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12664010.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kakishita E: IgD multiple myeloma preceding the development of extensive extramedullary disease without medullary involvement. Acta Haematol; 2000;104(1):42-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD multiple myeloma preceding the development of extensive extramedullary disease without medullary involvement.
  • We present a unique case of IgD multiple myeloma (MM) preceding the development of extensive extramedullary disease without medullary involvement.
  • A 63-year-old man was diagnosed with IgD-lambda MM when he developed anemia.
  • After 3 months of chemotherapy, he was in complete remission as evidenced by the disappearance of bone marrow (BM) plasmacytosis, monoclonal IgD protein in his serum, and Bence Jones proteinuria.
  • Six months after diagnosis, his disease took an unusual course with the development of plasmacytomas in the skin, without medullary involvement.
  • He then received chemotherapy, resulting in the complete disappearance of the subcutaneous plasmacytomas.
  • Two years after the initial diagnosis, his disease took an aggressive clinical course with retroperitoneal relapse, leading to the patient's death within 1 month.
  • This case provides evidence of two separate transformations of the original malignant MM clone.
  • [MeSH-major] Immunoglobulin D / blood. Multiple Myeloma / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cell Transformation, Neoplastic. Clone Cells / pathology. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Plasmacytoma / drug therapy. Plasmacytoma / enzymology. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11111122.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin D; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


17. Higurashi M, Yagishita S, Fujitsu K, Kitsuta Y, Takemoto Y, Osano S: Plasma cell myeloma of the skull base: report of two cases. Brain Tumor Pathol; 2004;21(3):135-41
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell myeloma of the skull base: report of two cases.
  • Plasma cell myeloma (PCM) of the skull base is rarely encountered in neurosurgical practice.
  • PCM has a wide spectrum of pathology, including a quite benign, solitary plasmacytoma (SPC), and an extremely malignant, multiple myeloma (MM) at the two ends of the spectrum.
  • The specimen and general examination, including bone marrow aspiration, revealed SPC.
  • The specimen revealed a plasmablastic tumor, i.e., myeloma.
  • General examination established the diagnosis of MM.
  • She was administrated adjuvant chemotherapy and autologous bone marrow transplantation.
  • [MeSH-major] Multiple Myeloma / pathology. Plasmacytoma / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696975.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Amine B, Benbouazza K, Harzy T, Rahmouni R, Guedira N, Lazrak N, Hajjaj-Hassouni N: IgD kappa myeloma: a new case. Joint Bone Spine; 2004 Jul;71(4):331-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD kappa myeloma: a new case.
  • IgD myeloma, which is particularly severe, accounts for only 1-3% of all myeloma cases, and the kappa subtype contributes only 10-30% of IgD myelomas.
  • CASE-REPORT: A 59-year-old man was admitted for inflammatory low back pain with L5 sciatica and diffuse bone pain.
  • Bone marrow aspirated from the sternum was found to contain 30% of malignant plasma cells.
  • Symptomatic treatment was given to correct the hypercalcemia, and combination chemotherapy was started.
  • DISCUSSION: IgD kappa myeloma is a severe variant of myeloma often associated with extraosseous lesions, renal failure, and amyloidosis.
  • The monoclonal component is absent or faint by serum protein electrophoresis, making the diagnosis difficult.
  • [MeSH-major] Immunoglobulin D. Immunoglobulin kappa-Chains. Multiple Myeloma / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chlorambucil / administration & dosage. Humans. Hypercalcemia / etiology. Hypercalcemia / pathology. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Renal Insufficiency / etiology. Renal Insufficiency / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15288860.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin kappa-Chains; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; MCP protocol
  •  go-up   go-down


19. Oh HS, Choi JH, Park CK, Jung CW, Lee SI, Park Q, Suh C, Kim SB, Chi HS, Lee JH, Cho EK, Bang SM, Ahn MJ: Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. Int J Hematol; 2002 Dec;76(5):465-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial.
  • Bone marrow angiogenesis has been reported to increase in several hematologic malignant diseases, including multiple myeloma.
  • Because high-dose chemotherapy combined with autologous stem cell transplantation (SCT) improves the response rate, event-free survival, and overall survival in patients with multiple myeloma (MM), we studied the changes in bone marrow microvessel density (MVD) in 21 patients who underwent high-dose chemotherapy combined with autologous SCT to determine whether there was persistently increased angiogenesis at the time of response.
  • Bone marrow biopsy specimens were obtained before and after SCT for each patient and immunostained with anti-CD34 antibodies for the identification of microvascular endothelial cells.
  • The mean value of MVD in 21 MM patients at initial diagnosis was 46.0 +/- 24.0 and in healthy controls was 26.8 +/- 8.54 (P = .046).
  • The mean MVD at initial diagnosis was 46.0 +/- 24.0 compared with 29.0 +/- 12.5 after achievement of response with SCT, and there was a statistically significant difference (P = .004).
  • In addition, the persistence of MVD at the time of response indicates continuous stimulus of microvessels by minimal residual disease even after SCT.
  • [MeSH-major] Multiple Myeloma / blood supply. Neovascularization, Pathologic. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Bone Marrow / pathology. Female. Humans. Male. Microcirculation. Middle Aged. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Apr 15;95(8):2630-6 [10753844.001]
  • [Cites] Histopathology. 1997 Mar;30(3):294-301 [9088964.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):353-6 [7535719.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1684-8 [9586879.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):349-54 [1503910.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] Br J Urol. 1994 Dec;74(6):762-6 [7530131.001]
  • [Cites] Br J Haematol. 1994 Jul;87(3):503-8 [7527645.001]
  • [Cites] Blood. 1989 Mar;73(4):865-79 [2465790.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Leukemia. 1999 Mar;13(3):469-72 [10086738.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 18;89(12):881-6 [9196255.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] Leuk Lymphoma. 1995 Dec;20(1-2):27-38 [8750620.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2438-50 [9059332.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):739-44 [8244569.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1649-55 [9269785.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2534-9 [9059344.001]
  • [Cites] Lancet. 1995 Aug 12;346(8972):388-90 [7542721.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2637-44 [10753845.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):815-21 [9060819.001]
  • (PMID = 12512842.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


20. Fallahi B, Beiki D, Mousavi SA, Gholamrezanezhad A, Eftekhari M, Fard-Esfahani A, Alimoghaddam K, Mirpour S, Eskandarian A, Saghari M: 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients. Hell J Nucl Med; 2009 Sep-Dec;12(3):255-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients.
  • Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM).
  • There is low sensitivity of technetium-99m methoxy isobutyl isonitrile ((99m)Tc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because (99m)Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP).
  • Thirteen patients had no previous history of treatment and 21 had a history of previous chemo-radiotherapy.
  • The diagnosis and staging of the disease were based upon routine laboratory and clinical criteria like bone marrow plasma cell count, serum M component, calcium, albumin, beta(2)-microglobulin.
  • Measurements of PGP and WBS using (99m)Tc-MIBI were performed before initialization of treatment and the response to treatment was assessed one year later.
  • The baseline (99m)Tc-MIBI WBS were considered positive for the detection of active lesions when at least one area of non-physiologic increased activity was noted.
  • Our results showed that for WBS, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy in active state for the diagnosis of MDR were 38.9%, 62.5%, 70%, 31.2% and 46.1%, respectively.
  • Also the above values for the detection of MDR, using PGP values were 50%, 50%, 69.2%, 30.8% and 50%, respectively.
  • The relative risk of resistant to multiple regimens of chemotherapy after one year follow up in patients with negative to patients with positive (99m)Tc-MIBI WBS was 1.02 (0.60-1.72).
  • In conclusion, we found a low sensitivity of WBS and of PGP in the detection of MDR in patients with active MM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / diagnosis. Multiple Myeloma / drug therapy. P-Glycoprotein / blood. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Whole Body Imaging / methods
  • [MeSH-minor] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936339.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


21. Schönland SO, Bochtler T, Kristen AV, Ho AD, Hegenbart U: [Current diagnostic and therapy of light chain amyloidosis]. Pathologe; 2009 May;30(3):205-11
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current diagnostic and therapy of light chain amyloidosis].
  • [Transliterated title] Aktuelle Diagnostik und Therapie der Leichtkettenamyloidose.
  • The light chain type is the most common form of systemic amyloidoses and has the worst prognosis.
  • The underlying disease is a monoclonal, mostly non-malignant plasma cell disorder.
  • The causative treatment is the reduction of the amyloidogenic light chains with conventional or high-dose chemotherapy.
  • Meanwhile, the"new drugs" used in multiple myeloma are also successfully applied.
  • Early diagnosis is important to be able to treat patients effectively and to avoid further deterioration of organ function.
  • Patients with newly diagnosed amyloidosis should be referred to a specialized center for consultation, diagnosis and treatment recommendation.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone Marrow / pathology. Diagnosis, Differential. Dose-Response Relationship, Drug. Early Diagnosis. Humans. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology. Plasma Cells / pathology. Protein Folding / drug effects. Referral and Consultation

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 May 1;111(9):4700-5 [18305218.001]
  • [Cites] Nephrol Dial Transplant. 2003 Dec;18(12):2644-7 [14605290.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1415-8 [17768110.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2578-84 [16293611.001]
  • [Cites] Blood. 2007 Jul 15;110(2):787-8 [17606766.001]
  • [Cites] Arthritis Rheum. 2008 Jul;58(7):1992-9 [18576343.001]
  • [Cites] N Engl J Med. 2007 Sep 13;357(11):1083-93 [17855669.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):673-80 [11274017.001]
  • [Cites] Amyloid. 2006 Sep;13(3):135-42 [17062379.001]
  • [Cites] Br J Haematol. 2004 Dec;127(5):543-51 [15566357.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23 ):1786-91 [12050338.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1888-93 [15155460.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3561-3 [17673601.001]
  • [Cites] Ann Intern Med. 2004 Jan 20;140(2):85-93 [14734330.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):625-35 [18070710.001]
  • [Cites] Haematologica. 2008 Mar;93(3):459-62 [18287137.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1062-6 [9920856.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):319-28 [16044444.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):262-7 [10458241.001]
  • [Cites] Haematologica. 2008 Jun;93(6):955-6 [18515883.001]
  • [Cites] Blood. 2006 May 1;107(9):3489-91 [16439680.001]
  • [Cites] Am J Transplant. 2005 Jul;5(7):1660-70 [15943624.001]
  • (PMID = 19343349.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amyloid; 0 / Antineoplastic Agents; 0 / Immunoglobulin Light Chains; 0 / amyloid protein AL
  • [Number-of-references] 29
  •  go-up   go-down


22. Hanaoka M, Tsukimori K, Hojo S, Abe Y, Mutou T, Muta K, Iwasa A, Yao T, Nakano H: B-cell lymphoma during pregnancy associated with hemophagocytic syndrome and placental involvement. Clin Lymphoma Myeloma; 2007 Jul;7(7):486-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 33-year-old Japanese woman developed pancytopenia, hepatosplenomegaly, and a high-grade fever for 2 weeks at 23 weeks of gestation.
  • The demonstration of hemophagocytes in her bone marrow confirmed the diagnosis of hemophagocytic syndrome.
  • Clinical manifestation suggested malignant lymphoma as the underlying cause of hemophagocytic syndrome, but we could not confirm any lymphoma involvement in the bone marrow aspiration.
  • Glucocorticoid therapy did not arrest the hemophagocytic process.
  • Using immunohistochemical study, we made the diagnosis of B-cell lymphoma.
  • R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy was administered on the eighth postpartum day.
  • After 2 cycles of R-CHOP chemotherapy, hematopoiesis became normal and hepatosplenomegaly almost completely disappeared.
  • After 6 cycles of R-CHOP, the patient received autologous peripheral-blood stem cell transplantation, and she is currently in complete remission 1 year after diagnosis.
  • The infant did well, without clinical or laboratory manifestations of malignant lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphohistiocytosis, Hemophagocytic. Lymphoma, B-Cell. Peripheral Blood Stem Cell Transplantation. Placenta. Pregnancy Complications, Hematologic. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Cesarean Section. Female. Fetal Distress / diagnosis. Fetal Distress / pathology. Fetal Distress / therapy. Gestational Age. Humans. Pregnancy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875240.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kobayashi T, Muto S, Nemoto J, Miyata Y, Ishiharajima S, Hironaka M, Asano Y, Kusano E: Fanconi's syndrome and distal (type 1) renal tubular acidosis in a patient with primary Sjögren's syndrome with monoclonal gammopathy of undetermined significance. Clin Nephrol; 2006 Jun;65(6):427-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fanconi's syndrome and distal (type 1) renal tubular acidosis in a patient with primary Sjögren's syndrome with monoclonal gammopathy of undetermined significance.
  • Fanconi's syndrome is a far less frequent complication compared with distal tubular dysfunction.
  • At that time, biclonal spike on serum protein (IgG-kappa and IgA-kappa) and Bence-Jones protein in urine were found.
  • Bone marrow aspiration showed 1.0% plasma cell infiltration.
  • Thus, a diagnosis of monoclonal gammopathy of undetermined significance (MGUS) was made.
  • Laboratory evaluation showed inappropriate, alkaline urine in hyperchloremic metabolic acidosis and a positive urine anion gap, indicating the presence of distal (Type 1) renal tubular acidosis (RTA).
  • No findings of multiple myeloma or malignant lymphoma were observed.
  • In conclusion, our patient had Sjögren's syndrome with MGUS and exhibited dysfunction of both proximal tubule (Fanconi's syndrome) and distal tubule, which may be attributed to diffuse tubulointerstitial nephritis.
  • [MeSH-major] Acidosis, Renal Tubular / complications. Fanconi Syndrome / diagnosis. Paraproteinemias / diagnosis. Sjogren's Syndrome / blood. Sjogren's Syndrome / complications






Advertisement